Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 2D6 17 and 29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity.

Clinical pharmacology and therapeutics - 1 Nov 2025

Kehinde Oyinlade, Vaughn Samuel E, Amaeze Ogochukwu, Toren Paul, Retke Brandon, Oni-Orisan Akinyemi, Ramsey Laura B

Abstract excerpt

CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6-metabolizing drugs. The objective of this study was to determine how sub-Saharan African-specific CYP2D6*17 and *29 alleles affect risperidone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antipsychotic Agents

Share to Black People

Share to Cytochrome P-450 CYP2D6

Share to Pharmacogenetics

Share to Precision Medicine

Share to Risperidone

Source

Open in PubMed Open full text

Identifiers

PMID: 40704440
DOI: 10.1002/cpt.70012
PMCID: PMC12558374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity.PMID 40704440Read ↗

Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles.Semantic proximity Read ↗

Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public healthSemantic proximity Read ↗

Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.Semantic proximity Read ↗

The Frequency of CYP2D6 and CYP3A4/5 Genotypes and The Impact of Their Allele Translation and Phenoconversion-Predicted Enzyme Activity on Risperidone Pharmacokinetics in Saudi Children with Autism.Semantic proximity Read ↗

Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens.Semantic proximity Read ↗

Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.Semantic proximity Read ↗

Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo.Semantic proximity Read ↗

CYP2D6 polymorphisms and their influence on risperidone treatmentSemantic proximity Read ↗

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Semantic proximity Read ↗

CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, AustraliaSemantic proximity Read ↗

Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population.Semantic proximity Read ↗

Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.